Sol-Gel Acquires Patidegib, Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate

 

to Pursue Potential Market of Over $300 Million

• Patidegib, an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDA
   
• Phase 3 study expected to initiate in the second half of 2023, with results expected by the end of 2025

Conference Call Information

Sol-Gel will host an investor conference call and webcast today at 8:30 a.m. U.S. ET to discuss today’s announcement.

To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins:

Domestic:  1-877-704-4453

International: 1-201-389-0920

Passcode: 13736097

The live conference call and replay can also be accessed by audio webcast here and also on the Investor Relations section of the Company’s website, located at https://ir.sol-gel.com/investor-relations. Slides for the accompanying corporate presentation can also be viewed at this link.

https://www.biospace.com/article/releases/sol-gel-acquires-patidegib-a-phase-3-fda-breakthrough-designated-orphan-product-candidate-to-pursue-potential-market-of-over-300-million/